Rapid response to pandemic flu
The rapid development, production, and distribution of pandemic influenza vaccines could potentially save millions of lives during an influenza pandemic. Due to the short time frame between identification of a pandemic strain and need for vaccination, researchers are looking at novel technologies for vaccine production that could provide better "real-time" access and be produced more affordably, thereby increasing access for people living in low- and moderate-income countries, where an influenza pandemic may likely originate, such as live attenuated (egg-based or cell-based) technology and recombinant technologies (proteins and virus-like particles). As of July 2009, more than seventy known clinical trials have been completed or are ongoing for pandemic influenza vaccines. In September 2009, the FDA approved four vaccines against the 2009 H1N1 influenza virus (the 2009 pandemic strain), and expected the initial vaccine lots to be available within the following month.In January 2020, the US Food and Drug Administration (FDA) approved Audenz as a vaccine for the H5N1 flu virus. Audenz is a vaccine indicated for active immunization for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine. Audenz is approved for use in persons six months of age and older at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine.
A more thorough categorization of lupus includes the following types:
acute cutaneous lupus erythematosus
subacute cutaneous lupus erythematosus
discoid lupus erythematosus (chronic cutaneous)
childhood discoid lupus erythematosus
generalized discoid lupus erythematosus
localized discoid lupus erythematosus
chilblain lupus erythematosus (Hutchinson)
lupus erythematosus-lichen planus overlap syndrome
lupus erythematosus panniculitis (lupus erythematosus profundus)
tumid lupus erythematosus
verrucous lupus erythematosus (hypertrophic lupus erythematosus)
cutaneous lupus mucinosis
complement deficiency syndromes
drug-induced lupus erythematosus
neonatal lupus erythematosus
systemic lupus erythematosus

Treatment
There is still no cure for lupus but there are options to help control symptoms. The goal for treatment is to prevent flare ups and reduce organ damage. Doctors may prescribe a handful of different medications to help with their patients symptoms.Some medications are:

Nonsteroidal anti-inflammatory drugs (NSAIDs). Corticosteroids
Antimalarial drugs
BLyS-specific inhibitors
Immunosuppressive agents/chemotherapyAfter being diagnosed some treatment options that may be offered are:

Treatment consists primarily of immunosuppressive drugs (e.g., hydroxychloroquine and corticosteroids). A second-line drug is methotrexate in its low-dose schedule. In 2011, the U.S. Food and Drug Administration (FDA) approved the first new drug for lupus in more than 50 years to be used in the US, belimumab. In addition to medical therapy, cognitive behavioral therapy has also been demonstrated to be effective in reducing stress, anxiety, and depression due to the psychological and social impacts that lupus may have.People with SLE treated with standard care experience a higher risk of opportunistic infections and death than the general population. This risk is higher in men and in African Americans. Epidemiology
Worldwide
An estimated 5 million people worldwide have some form of lupus disease. 70% of lupus cases diagnosed are systemic lupus erythematosus.